Policy Work and Research
The IDEA Initiative conducts policy analysis, carries out research projects, and contributes to expert advisory processes to support and inform work to address global health challenges, from antimicrobial resistance to innovation and access to health technologies.
The IDEA Initiative serves as the Strategic Policy Program for ReAct--Action on Antibiotic Resistance and as the Secretariat for the Antibiotic Resistance Coalition. In these roles, we carry out and support:
briefings for policymakers and civil society (e.g., “Bridging the GAP: A Policy Briefing on Next Steps for Tackling Antimicrobial Resistance” for the WHO Executive Board, January 2017)
policy convenings for the Antibiotic Resistance Coalition, such as the annual WHO-NGO Dialogue on Antimicrobial Resistance, a civil society roundtable in Washington, DC with the WHO AMR Secretariat, and the Tripartite agency teleconsultation on the Global Development and Stewardship Framework on Antimicrobial Resistance, and for other groups (e.g., Junior Doctors Network of the World Medical Association)
joint position statements for the Antibiotic Resistance Coalition (e.g., to the UN Interagency Coordination Group on Antimicrobial Resistance and on the Tripartite Monitoring and Evaluation Framework)
strategy convenings for ReAct (e.g., Globalizing Food Campaigns: Sharing Strategies to Address Antimicrobial Resistance) and the Antibiotic Resistance Coalition
educational campaigns on key AMR policy issues (e.g., a Thunderclap campaign that generated over 660,000 Tweets in support of “Use Antibiotics Responsibly in Our Food System” timed with the Prince Mahidol Awards Conference in January 2018)
The Program has been called upon to serve in various expert advisory roles, contributing to the:
Antibiotic Resistance Working Group, U.S. President’s Council of Advisors in Science and Technology
Expert Commission on Addressing the Livestock Contribution to the Antibiotic Resistance Crisis and its report, “Combating Antibiotic Resistance: A Policy Roadmap to Reduce Use of Medically Important Antibiotics in Livestock”
The program conducts research spanning the One Health dimensions of antimicrobial resistance.
This ranges from commissioned papers, such as for UK Review on Antimicrobial Resistance on “A Framework for Costing the Lowering of Antimicrobial Use in Food Animal Production”) and for WHO on “Building a Global Framework for Antimicrobial Development and Stewardship”
contributions to special journal supplements
So AD, Shah TA, Roach S, Ling Chee Y., and Nachman KE. An Integrated Systems Approach is Needed to Ensure the Sustainability of Antibiotic Effectiveness for Both Humans and Animals. J Law Med Ethics 43 Suppl 3, 38–45. June 2015.
So AD and Shah TA. New business models for antibiotic innovation. Uppsala Journal of Medical Sciences, 2014; 119(2), 176-180.
So AD, Bigdeli M, Tomson G, Woodhouse W, Ombaka E, Peralta AQ. Part 5: The access and excess dilemma. “Antibiotic resistance—the need for global solutions,” The Lancet Infectious Diseases Commission 2013 Dec; 13(12): 1057-98.
So AD, Gupta N, Brahmachari SK, Chopra I, Munos B, Nathan C, Outterson K, Paccaud JP, Payne DJ, Peeling RW, Spigelman, M, Weigelt J. Towards new business models for R&D for novel antibiotics. Drug Resistance Updates. 2011;14(2): 88-94.
analyses of pharmaceutical innovation of novel classes of antibiotics
Freire-Moran L, Aronsson B, Manz C, So AD, Monnet DL, Cars O, the ECDC-EMA Working Group. Critical shortage of new antibiotics in development against multidrug-resistant bacteria—Time to react is now. Drug Resistance Updates. 2011;14(2): 118-124.
So AD, Ruiz-Esparza Q, Gupta N, Cars O. 3Rs for Innovating Conserving Novel Antibiotics: Sharing Resources, Risks and Rewards. British Medical Journal. 2012; 344:e1782.